Breath test hope for lung cancer diagnosis
Respiratory experts are to evaluate a device for early stage cancer detection.
Led by a team at Leicester University, the clinical trial is set to commence at the city’s Glenfield Hospital. It is hoped that the LuCID (Lung Cancer Indicator Detection) programme will lead to a non-invasive method of diagnosing early stage lung cancer.
The company behind the device, Cambridge-based Owlstone Nanotech, carried out a health economic analysis and determined that detection of early-stage lung cancer could be increased from the current 14.5 per cent to 25 per cent by 2020, saving around 10,000 lives and £250m of the NHS’s funds.
The device works by measuring volatile organic compounds (VOCs) at low concentrations in a patient’s breath and is claimed to offer a cheaper and smaller alternative to existing detection technologies.
Supported by the Leicester University ’s enterprise and business development team and Leicester’s Hospitals, Owlstone was awarded £1m by the NHS Small Business Research Initiative (SBRI) towards clinical trials of the LuCID project.
Register now to continue reading
Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.
Benefits of registering
-
In-depth insights and coverage of key emerging trends
-
Unrestricted access to special reports throughout the year
-
Daily technology news delivered straight to your inbox
Radio wave weapon knocks out drone swarms
Probably. A radio-controlled drone cannot be completely shielded to RF, else you´d lose the ability to control it. The fibre optical cable removes...